Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03485599
Other study ID # PKHIVL
Secondary ID
Status Not yet recruiting
Phase
First received March 21, 2018
Last updated March 30, 2018
Start date January 2019
Est. completion date April 2020

Study information

Verified date March 2018
Source Assiut University
Contact Hisham Zayan, Assistant
Phone 01223971409
Email hishamzayan@icloud.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Human immunodeficiency virus infection is a global pandemic problem. About 35.3 million infected people in the world, so causing a great social, economical, political and cultural problems worldwide.

In 1986 Egypt's first AIDS case was discovered , since then the number of infected cases cases are increasing.According to United Nations 2016 statistics, there are about 11,000 infected people living with Human immunodeficiency virus in Egypt.


Description:

Human immunodeficiency virus is a lentivirus that causes the infection and over time leading to Acquired immunodeficiency syndrome.

The virus spread primarily by unprotected sex including vaginal, anal and oral sex, contaminated blood transfusions, infected needles, and from mother to child during pregnancy, delivery, or from milk during breastfeeding.

In 1986 Egypt's first AIDS case was discovered , since then the number of infected cases cases are increasing.According to United Nations 2016 statistics, there are about 11,000 infected people living with Human immunodeficiency virus in Egypt.

According to the National Aids Program, the primary mode of transmission is heterosexual intercourse, followed by homosexual intercourse , renal dialysis , and blood transfusion Others include street children, prisoners, and refugees, female sex workers, men have sex with men, and injecting drug users.

Human immunodeficiency virus related stigma and discrimination is a great barrier to effectively fighting the disease epidemic.

This study will assess prevalence, knowledge, attitudes of Human immunodeficiency virus and Acquired immunodeficiency syndrome people in Luxor Governorate in Upper Egypt.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 400
Est. completion date April 2020
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

1-People living in Luxor. 2 Subjects of high risk groups as men have sex with men, children street, female sex workers.

3-People clinically diagnosed as HIV/AIDS. 4-People in contact with HIV/AIDS patients.

Exclusion Criteria:

1 - Subjects outside Luxor 2- People refused to consent 3- Mentally disordered patients

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
ELIZA , Westron blot
Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done

Locations

Country Name City State
Egypt Faculty of Medicine Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (3)

Abstracts from the 38th annual meeting of the society of general internal medicine. J Gen Intern Med. 2015 Apr;30 Suppl 2:45-551. doi: 10.1007/s11606-015-3271-0. — View Citation

Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest. 2008 Apr;118(4):1244-54. doi: 10.1172/JCI34706. Review. — View Citation

Getnet MK, Damen HM. Level of stigma among female sex workers: comparison of two surveys of HIV behavioral data, Ethiopia. Afr Health Sci. 2011 Dec;11(4):543-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary knowledge score Questionnaire to define knowledge score of HIV/AIDS through an interview 20 mintues
See also
  Status Clinical Trial Phase
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03215901 - Life Plans Intervention Study N/A
Completed NCT03289676 - Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV Phase 1
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Active, not recruiting NCT04064567 - Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK N/A
Completed NCT04013295 - Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya N/A
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT03984136 - HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM N/A
Completed NCT02928900 - Patient Actor Training to Improve HIV Services for Adolescents in Kenya N/A
Recruiting NCT03268109 - COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
Completed NCT02797262 - Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System N/A
Completed NCT02376582 - Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS Phase 1
Completed NCT01957865 - Real-Time Antiretroviral Therapy Adherence Intervention in Uganda N/A
Completed NCT01616940 - Minority AIDS Initiative Retention and Re-Engagement Project N/A
Terminated NCT01443923 - Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV Phase 4
Completed NCT01910714 - Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth N/A
Completed NCT01084421 - A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos N/A
Completed NCT01596322 - International HIV Antiretroviral Adherence, Resistance and Survival N/A
Completed NCT03643705 - A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention N/A
Completed NCT03923231 - Pharmacokinetics of Atazanavir in Special Populations